| Company Name: |
ChemCell Biomedicine Co.,Ltd.
|
| Tel: |
020-13556033878 2965585218 13556033878 |
| Email: |
chemcell@hotmail.com |
| Products Intro: |
Product Name:Ralmitaron
CAS:2133417-13-5
Purity:98% Package:5mg；10mg；20mg；50mg；100mg；250mg；500mg；1g；5g；10g；25g；100g
|
|
| | 1H-Pyrazole-3-carboxamide, 5-ethyl-4-methyl-N-[4-(2S)-2-morpholinylphenyl]- Basic information |
| Product Name: | 1H-Pyrazole-3-carboxamide, 5-ethyl-4-methyl-N-[4-(2S)-2-morpholinylphenyl]- | | Synonyms: | 1H-Pyrazole-3-carboxamide, 5-ethyl-4-methyl-N-[4-(2S)-2-morpholinylphenyl]-;RO6889450;Ralmitaront HCl;Ralmitaront (WHO-11130;RG-7906);RO 6889450,TAAR1,Schizoaffective Disorder,Inhibitor,SCZ,Ralmitaront,Negative Symptom,inhibit,Schizophrenia,RO-6889450;Ralmitaron;5-ethyl-4-methyl-N-{4-(2S)-morpholin-2-ylphenyl}-1Hpyrazole-3-carboxamide hydrochloride | | CAS: | 2133417-13-5 | | MF: | C17H22N4O2 | | MW: | 314.38 | | EINECS: | | | Product Categories: | | | Mol File: | 2133417-13-5.mol | ![1H-Pyrazole-3-carboxamide, 5-ethyl-4-methyl-N-[4-(2S)-2-morpholinylphenyl]- Structure](CAS/20200611/GIF/2133417-13-5.gif) |
| | 1H-Pyrazole-3-carboxamide, 5-ethyl-4-methyl-N-[4-(2S)-2-morpholinylphenyl]- Chemical Properties |
| Boiling point | 489.971±45.00 °C(Press: 760.00 Torr)(predicted) | | density | 1.222±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 100 mg/mL (318.09 mM; Need ultrasonic) | | form | Solid | | pka | 11.990±0.70(predicted) | | color | White to off-white |
| | 1H-Pyrazole-3-carboxamide, 5-ethyl-4-methyl-N-[4-(2S)-2-morpholinylphenyl]- Usage And Synthesis |
| Uses | Ralmitaront (RO6889450) is an orally active agonist of trace amine-associated receptor 1 (TAAR1) with a EC50 value of 110.4 nM. Ralmitaront has antipsychotic, cognitively improvement, and antidepressant activity in rodents. Ralmitaront can be used as a neurosuppressant in the study of neuro-related diseases, such as schizophrenia (SCZ), schizoaffective disorder[1][2][3][4]. | | IC 50 | TAAR1 | | References | [1] Linda S Brady, et al. Redirecting the revolution: new developments in drug development for psychiatry. Expert Opin Drug Discov. 2019 Dec;14(12):1213-1219. DOI:10.1080/17460441.2019.1666102
[2] Halff EF, et al. Trace amine-associated receptor 1 (TAAR1) agonism as a new treatment strategy for schizophrenia and related disorders. Trends Neurosci. 2023 Jan;46(1):60-74. DOI:10.1016/j.tins.2022.10.010
[3] gren R, et al. In Vitro Comparison of Ulotaront (SEP-363856) and Ralmitaront (RO6889450): Two TAAR1 Agonist Candidate Antipsychotics. Int J Neuropsychopharmacol. 2023 Sep 25;26(9):599-606. DOI:10.1093/ijnp/pyad049
[4] Yu J, et al. Elucidating the molecular pharmacology of trace amine-associated receptor 1 to advance antipsychotic drug discovery. Clin Transl Med. 2024 Feb;14(2):e1576. DOI:10.1002/ctm2.1576 |
| | 1H-Pyrazole-3-carboxamide, 5-ethyl-4-methyl-N-[4-(2S)-2-morpholinylphenyl]- Preparation Products And Raw materials |
|